​

MiNK Therapeutics Stock (NASDAQ:INKT)

ForecastOwnershipFinancialsChartTranscripts
MiNK Therapeutics by TradingView

Previous Close

$11.82

52W Range

$6.80 - $76.00

50D Avg

$11.49

200D Avg

$12.28

Market Cap

$60.73M

Avg Vol (3M)

$54.91K

Beta

0.47

Div Yield

-

INKT Company Profile

MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

23

IPO Date

Oct 15, 2021

Website

INKT Performance

INKT Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income-$-10.65M$-22.92M
Net Income$-12.49B$-10.78M$-22.46M
EBITDA-$-10.57M$-22.25M
Basic EPS$-2.93$-2.90$-6.54
Diluted EPS$-2.93$-2.80$-6.54

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Mar 31, 26 | 8:30 AM
Q3 25Nov 14, 25 | 8:30 AM
Q2 25Aug 14, 25 | 8:30 AM

Peer Comparison

TickerCompany
OSTXOS Therapies Incorporated
OTLKOutlook Therapeutics, Inc.
CRVOCervoMed Inc.
SPRBSpruce Biosciences, Inc.
NRXPNRx Pharmaceuticals, Inc.
IOBTIO Biotech, Inc.
EQEquillium, Inc.
HOWLWerewolf Therapeutics, Inc.
VTVTvTv Therapeutics Inc.
GANXGain Therapeutics, Inc.